Literature DB >> 25958927

The effects of mycophenolate mofetil on cytokines and their receptors in pulmonary arterial hypertension in rats.

Y F Zhang1, Y Zheng1.   

Abstract

OBJECTIVES: To analyse the effects of mycophenolate mofetil (MMF) on pulmonary artery pressure (PAP) and the expression of cytokines and their receptors in a rat model of pulmonary arterial hypertension (PAH).
METHOD: Thirty-eight healthy male inbred Sprague-Dawley rats were divided randomly into four groups: a control group, a monocrotaline (MCT) group, an MMF20 group (MCT+20 mg/kg/day MMF), and an MMF40 group (MCT+40 mg/kg/day MMF). Systolic PAP (SPAP), the right ventricular hypertrophy index (RVI), and the levels of expression of cytokines and their receptors were measured and analysed.
RESULTS: SPAP, RVI, levels of expression of basic fibroblast growth factor (bFGF) in serum and lung homogenates, alveolar arterial wall thickness, and the number of muscular arteries in the MMF20 and MMF40 groups were decreased in comparison with the MCT group.
CONCLUSIONS: MMF inhibits the formation of vascular muscle and decreases SPAP and RVI by inhibition of the expression of bFGF, endothelin-1 (ET-1), and their receptors, resulting in the inhibition of smooth muscle proliferation and amelioration of PAH.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25958927     DOI: 10.3109/03009742.2015.1023829

Source DB:  PubMed          Journal:  Scand J Rheumatol        ISSN: 0300-9742            Impact factor:   3.641


  2 in total

Review 1.  Pulmonary arterial hypertension in connective tissue disorders: Pathophysiology and treatment.

Authors:  Elisabetta Zanatta; Pamela Polito; Giulia Famoso; Maddalena Larosa; Elena De Zorzi; Elena Scarpieri; Franco Cozzi; Andrea Doria
Journal:  Exp Biol Med (Maywood)       Date:  2019-01-22

2.  Mycophenolate mofetil for scleroderma-related interstitial lung disease: A real world experience.

Authors:  Misbah Baqir; Ashima Makol; Thomas G Osborn; Brian J Bartholmai; Jay H Ryu
Journal:  PLoS One       Date:  2017-05-25       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.